The limitations of current pharmacotherapies for depression highlight the need for rapid acting antidepressants. The glutamate mechanisms in major depressive disorder have attracted much attention in recent years as a promising target for developing novel antidepressants. NR2A-and NR2B-containing NMDA receptors are considered as the major isoforms of functional NMDA receptor channels in CNS neurons. Deathassociated protein kinase 1 (DAPK1) couples NR2B subunits at extrasynaptic sites to regulate the NMDA receptor channel conductance. However, still unknown is the involvement of DAPK1 and NR2B subunit interaction in the rapid antidepressant effect. Here we found high glutamate abundance accompanied by high expression of DAPK1, p-NR2B at Ser1303 and low expression of p-CREB, BDNF and synaptic proteins in the medial prefrontal cortex of rats that were subjected to chronic unpredictable mild stress (CUS). Blockade of astrocytic glutamate transporter-1 in the mPFC is sufficient to induce depression-like behavior and cause similar molecular changes. Administration of DAPK1 inhibitor and selective NR2B antagonist but not NR2A antagonist produced a rapid antidepressant effect. Uncoupling DAPK1 from NR2B subunit by application of cell membrane permeable Tat-NR2B CT peptide also produced a rapid antidepressant effect by reducing the immobility in the forced swim test and reversing CUS-induced decrease in sucrose preference. Moreover, we found that selective NR2B antagonist did not produce rewarding effect measured with conditioned place preference paradigm. Together, our findings suggest that DAPK1 interaction with NMDA receptor NR2B subunit acts as a critical component in the rapid antidepressant actions.
PS127
Antidepressant amitriptyline activates matrix metalloproteinase in astroglial cells: involvement in glial cell line-derived neurotrophic factor expression. 
Hiroshima University Graduate School of Biomedical Sciences, Japan
Abstract Background: Glial cells, especially astrocytes have been implicated in the pathophysiology of mood disorder and the efficacy of antidepressants. The tricyclic antidepressant amitriptyline induces a Gα i/o /matrix metalloproteinase (MMP)/fibroblast growth factor receptor (FGFR)/ERK cascade, which is crucial for glial cell line-derived neurotrophic factor (GDNF) mRNA expression in rat C6 astroglial cells (C6 cells), primary astrocytes. However, the identity of the MMP involved has yet to be identified. The current study identified the mechanism of MMP activation induced by amitriptyline and the MMP subtypes involved. Methods: C6 cells and primary astrocytes were used in the following experiments. The level of GDNF mRNA was measured by real-time PCR and the activity of MMP-2, -9 was measured by gelatin-zymography. Results: Matrix metalloproteinase-2, -3 and -9 were expressed in C6 cells. Following amitriptyline treatment, MMP-9 activity in culture medium increased without any change in mRNA levels, whereas no change in MMP-2 activity was observed. A similar response with MMP-9 was observed with different classes of antidepressants, but not with drugs lacking antidepressant activity and monoamines. Amitriptyline-induced ERK activation/GDNF mRNA expression was blocked by MMP-3 and MMP-9 inhibition, but not by MMP-2 inhibition. Treatment with exogenous MMP-3 and MMP-9 increased GDNF mRNA expression. Amitriptyline-induced MMP-9 activation was suppressed with MMP-3 inhibition and exogenous MMP-3-induced GDNF mRNA expression was suppressed by MMP-9 inhibition, indicating that MMP-3 regulates MMP-9 activity. The FGFR-induced ERK/GDNF cascade was not blocked by MMP inhibition, indicating that MMP activation is upstream of FGFR activation. Furthermore, amitriptyline-induced MMP-9 activation is not direct but via intracellular signaling, as Gα i/o inhibition and Src family tyrosine kinases inhibition blocked amitriptyline-induced MMP-9 activation.
Conclusion:
The current results elaborate a potential non-monoamine mediated mechanism of antidepressant action involving MMP activation and intracellular signaling in astrocytes.
PS128
Ketamine R(-) and S(+) Pharmacological Actions; Together or Separate Rapid Acting Antidepressants
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109
Abstract It is well documented that low dose racemic ketamine, a mixture of two enantiomers, has a rapid antidepressant effect within hours that may last for 1 to 2 weeks. Racemic ketamine probably will never become a major treatment of depression because it has significant schizophrenomimetic and drug abuse side effects. The mechanism of its rapid antidepressant actions continues to be a major target of current and future research. This presentation addresses the fact that the two enantiomers of racemic ketamine have overlapping but also different pharmacological actions that target either antidepressant, analgesic or anesthetic uses. Detailed pharmacological dose-effect studies for each enantiomer and their metabolites must involve classic basic science methodology. A wide range of ketamine concentrations vary from 50-10000 ng/ml (0.21 -42.1 nmol/ml) in vitro and in vivo. After i.v administration, anesthetic concentrations are greater than 2,000 with peak levels as high as 10,000 ng/ml. Patients return to consciousness ~1,100 ng/ml. Low dose ketamine has analgesic and antidepressant effects with venous plasma concentrations of ~150 ng/ml i.v. and as low as 40 ng/ml oral administration. Given a preferential distribution of ketamine brain:plasma ratio of 6.5, its equivalent concentration is ~227 ng/ml in brain. In vitro NMDAR antagonism has a Ki value of ~190 ng/ml for S-(+)-ketamine and ~360 ng/ml for R(-)-ketamine. These are similar to the low concentrations for antidepressant effects. In vivo, a low dose of racemic ketamine also inhibits serotonin reuptake. Compared to S-(+)-ketamine, the less potent anesthetic enantiomer R(-)-ketamine requires much more additional concentration effect studies for its analgesic and antidepressant effects.
PS129
Low TNFAIP3 was normalized with antidepressant in patients with major depressive disorder
Yi-Yung Hung Chang Gung Memorial Hospital, Taiwan
Abstract Rationale: Abnormalities in Toll-like receptors (TLRs) expression in depression have been inferred in part from observed increases in TLR4 levels in peripheral blood mononuclear cells (PBMCs) and postmortem brains of depressed and suicidal patients. Activation of the TLR4 pathway partially explained the inflammatory status in patients with major depressive disorder. However, the negative regulators for TLR4 pathway have never been investigated. Objectives: In vivo, the mRNA expression levels of negative regulation genes including SOCS1, TOLLIP, SIGIRR, MyD88, NOD2, and TNFAIP3 in PBMCs were examined in 56 patients with MDD and 35 health controls. The mRNA expression levels were assessed in parallel with a housekeeping gene using qRT-PCR before and after treatment with antidepressants. We also investigated the in vitro effects of fluoxetine on the TNFAIP3 expression. First, TNFAIP3 in human monocytes (THP-1 cell line) was measured by qRT-PCR after treated with fluoxetine (10⁻⁸-10⁻⁵ M). Second, we pretreated monocytes, which had TNFAIP3 gene knockdown, with fluoxetine before LPS-stimulation. Then, interleukin 6 (IL-6) and tumor necrotic factor alpha (TNFα) were measured by qRT-PCR. Results: In vivo, TOLLIP, MyD88, NOD2 and TNFAIP3 were expressed at lower levels in patients with MDD. Only TNFAIP3 was significantly increased and normalized by treatment with antidepressants for 4 weeks. In vitro, fluoxetine could significantly increase TNFAIP3 mRNA expression in human monocyte. The suppressive effects of fluoxetine on IL-6 and TNFα decreased partially after knockdowning TNFAIP3 gene. Conclusions: These findings suggest that antidepressant treatment exerts anti-inflammatory effects in patients with MDD partially through increasing expression of TNFAIP3 gene. Further studies investigating the effects of manipulating TNFAIP3 gene on depression is needed to fully elucidate the underlying mechanism. Keywords: negative regulation, toll-like receptor, innate immunity, major depressive disorder, inflammation
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Maternal fluoxetine treatment influences anxiety-and depressive-like behaviours in adolescent offspring: a rodent model Kelly A. Newell, Samuel Millard, Connor Mackay, Marta Ramos, Rebecca Webby, Jeremy S. Lum, Francesca Fernandez. University of Wollongong, Australia,
Abstract
Objective: Approximately 10% of pregnant women are prescribed antidepressant drugs, most commonly the selective serotonin reuptake inhibitor, Fluoxetine. Fluoxetine crosses the placenta and is excreted in breast milk raising concerns regarding the consequences of infant exposure. The aim of this study was to evaluate the effects of maternal Fluoxetine treatment on offspring behaviours of relevance to neurodevelopmental and psychiatric disorders, using a rodent model of depression. Methods: Sprague-Dawley (SD; healthy model) and WistarKyoto (WKY; depression model) pregnant rats were treated with Fluoxetine (10mg/kg/day) or vehicle, from gestational day 0 to postnatal day 14 (~5 weeks in total). Once offspring reached adolescence (~5 weeks of age), locomotor activity, anxiety-like and depressive-like behaviours were assessed using the open field test (OFT), elevated plus maze (EPM) and forced swim test (FST). Results: Fluoxetine exposed offspring displayed an increase in distance travelled in the OFT, an effect that was independent of rat strain and sex. Fluoxetine exposure also caused an increase (up to 50%) in time spent in the corners of the OFT in SD male and WKY female rats compared to their respective vehicle controls. Similarly, in the EPM, maternal Fluoxetine treatment resulted in a significant increase in time spent in the closed arms in SD males and WKY males (29-52%). A similar trend was observed in females, but this did not reach significance. In the FST, maternal Fluoxetine treatment increased immobility time in exposed offspring (28%), an effect that was independent of strain or sex. Conclusion: Maternal Fluoxetine treatment resulted in significant increases in anxiety-like and depressive-like behaviours in exposed offspring, largely independent of the rat model used. However, further studies in various models of maternal depression are required to confirm these preliminary findings and establish the effects of Fluoxetine exposure on the developing brain.
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Transcriptomic evidence for dematuration of the mouse frontal cortex and hippocampus by chronic antidepressant treatment 
Abstract
The selective serotonin reuptake inhibitor, fluoxetine (FLX), is widely used to treat depression and anxiety disorders, but mechanisms underlying its antidepressant effect remain largely unknown. Previous studies that evaluated several molecular and/or electrophysiological features of the maturation stages of each neuron type have demonstrated that FLX treatment can reverse the established maturation of certain types of neurons in the hippocampus and frontal cortex (FC). However, this dematuration effect of FLX in the adult brain has not been assessed with regard to genome-wide gene expression patterns.
In this study, we compared gene expression patterns in the FLX-treated FC and hippocampus of adult mice with those of the corresponding brain regions of normal infant mice. The gene expression patterns of FLX-treated mice significantly resembled those of normal infant mice in the FC and, to a large extent, in the hippocampus. In addition, time-course analyses of the ages of infant mice used in the comparisons with FLX-treated mice indicated that the gene expression patterns of FLX-treated mice were most similar to those of the youngest infants examined (1-week-old hippocampus and 2-week-old FC).
